Dr. Andersen-Nissen is a principal staff scientist in the Vaccine and Infectious Disease Division of Fred Hutch and directs the Cape Town HVTN Immunology Lab in South Africa. She joined the HVTN in 2011 and leads cellular and innate immunology studies of HIV, TB and COVID vaccines to understand vaccine immunogenicity and immune correlates of risk and protection.

A registered nurse with a background in HIV/AIDS care and infectious diseases, Anderson leads the Clinical Safety team and monitors participant safety and ensures consistent, accurate clinical trial data. Anderson joined Fred Hutch in 2009 and HVTN in 2014. She holds a Master of Nursing with an infectious disease focus, a Bachelor of Science in Nursing, and a Bachelor of Arts in Women Studies, all from the University of Washington.

Dr. Andrasik is a clinical health psychologist who has led the HVTN’s social, behavioral, and implementation science programs for more than 15 years.  She partners closely with communities, community-based organizations, and clinical research site staff to advance participant-centered, trauma informed research and is an expert in community-engaged research, HIV prevention, and qualitative methods.

Sally Bock has over 25 years of experience in brand marketing. She joined the CoVPN after leading the Fred Hutch marketing team. Her experience ranges from Fortune 500 companies to emerging brands, as well as across many high-impact sectors, including health care, technology (SaaS, Cloud, satellite), consumer brands, social impact, higher education, and arts & culture institutions.

Huub Gelderblom is a physician-scientist who joined HVTN in 2019 and again in 2022. Huub has an MD, MSc and PhD from the University of Amsterdam, and an MPH from New York University. He has extensive experience working on HIV, hepatitis C, trachoma and SARS-CoV-2 in Europe, Africa, and the US. Huub works on the clinical development for broadly neutralizing antibodies for HIV prevention (also known as passive immunization and passive immunoprophylaxis).

Meg is a regulatory leader with over 18 years of experience in clinical research compliance, IRB, and cross-functional project management. Before the HVTN, she “cut her chops” at a commercial IRB (Quorum Review IRB, now part of Advarra) but wanted to get closer to the action. She joined the HVTN in 2016 for the AMP trials, and since then has worked on other antibody studies, ATI trials in PLWH, and Phase 1 HIV vaccine studies in PLWoH. 

Gail Broder joined the HIV Vaccine Trials Network in 2003 and works with educators and communities at global clinical trial sites to educate and raise awareness about biomedical HIV prevention, including HIV vaccines and monoclonal antibodies, TB vaccines, and analytical treatment interruption trials. She regularly presents on the Community Engagement work conducted by the HVTN and has co-authored over 30 posters and papers. She obtained her Masters Degree in Health Science with emphasis in Health Education from Washington University in St. Louis, Missouri.

William Hahn is clinically trained in infectious disease. During fellowship, his research experience involved the link between the innate and adaptive immune response in preclinical models of malaria. He joined the HVTN in 2019 and has worked primarily on early-phase vaccine trials.

Dr. Hural holds a PhD in Immunology and Molecular Pathogenesis and has over 25 years of experience in vaccine development and clinical trials. He has led the HVTN Laboratory Operations group for more than two decades. This group oversees and coordinates all laboratory activities related to HVTN clinical trials, including immunologic and virologic endpoint monitoring, specimen processing, HIV diagnostics, viral genetics, specimen repositories, and safety testing.

Carissa Karg joined the HVTN in 2009 and is the Senior Director of Network Operations. Prior to her current role, she was a Clinical Trials Manager, the Associate Director of Site Operations, and the Director of Site Operations at the HVTN. She has a wealth of experience with implementation, oversight, and operations of HVTN HIV vaccine and antibody clinical trials. She has an MPH with a special interest in HIV/AIDS and other infectious diseases.

Dr. Mondal joined the HVTN in 2020 and leads protocol development for the network's portfolio of TB, HIV vaccine and monoclonal antibody clinical trials. She works with clinical, statistical, laboratory, regulatory and operations teams, and with NIH/DAIDS, to move studies from concept to activation. She holds a Ph.D. in Molecular Biophysics from the Indian Institute of Science.

Michelle Nebergall is the Associate Director for Site Operations - Africa at the HVTN and has been based in Johannesburg, South Africa since 2014, supporting the HVTN’s trials across the continent. She oversees clinical trial operations and clinical research site development for HIV, COVID-19, and tuberculosis vaccine research.

Laurie Rinn is a public health professional with more than 20 years of experience in clinical research in the non-profit and global health fields. She has worked in project management, clinic coordination, and regulatory affairs in the fields of oncology, malaria and COVID-19 and HIV vaccine research.

As the Associate Director of Finance and Contracts at Fred Hutch, Vivianne Rotich oversees the full cycle financial activities including clinical trials budgeting, financial reporting and management, and serves as the point of contact on financial matters.

Dr. Roxby is a physician-scientist and Associate Professor of Medicine, Global Health and Epidemiology at University of Washington. Dr. Roxby’s research focuses on HIV and STI prevention in women and strategies to prevent Covid-19. Roxby works to expand the HVTN to include the next generation of HIV vaccine researchers.

As Stakeholder Relations and Engagement Director, Louis leads the engagement of external partners and public communications for the HVTN. Louis’ work includes guiding HVTN stakeholder engagement strategies, spearheading community partnerships, crafting external study communications, and developing research awareness and educational initiatives.

Carrie Sopher holds a Master of Public Health degree and brings more than 15 years of experience in clinical research and trial operations. She joined the HVTN in 2010 as a Project Manager in the Network Evaluation Unit before transitioning to the Site Operations Unit in 2016 as a Clinical Trials Manager. Carrie subsequently served as Associate Director of Site Operations and was appointed Director of Site Operations in 2025. Throughout her career, she has developed extensive expertise in clinical trial implementation, research site development, and operational support, helping to advance high-quality clinical research across diverse settings.

Dr. Villaran is a graduate of the Universidad Peruana Cayetano Heredia Medical School in Lima, Peru, received a Master of Science in International Public Health and Tropical Disease from Humboldt University Berlin, Germany and a Master of Public Health from the University of Washington.